Fosamax Information and Problems
The osteoporosis drug Fosamax has been associated with an increased risk of jaw and bone decay. Lawsuits are being reviewed nationwide. >>REQUEST A CONSULTATION
Fosamax (generic name alendronate sodium) is a bisphosphonate medication prescribed for treatment and prevention of osteoporosis, osteopenia and Paget’s disease of the bone.
The medication increases bone mass density and reduces the occurrence of fractures for patients with osteoporosis. However, studies have shown that it has the opposite effect in the jawbone and major joints like the hip, shoulder, and knee, leading to infections and easily breakable bones.
The manufacturers of Fosamax, Merck, failed to adequately warn about the risk of jaw problems and bone deterioration. The lawyers at Saiontz & Kirk, P.A. are reviewing potential lawsuits for individuals who have been diagnosed with osteonecrosis of the jaw, osteonecrosis of the hip, osteonecrosis of the knee or osteonecrosis of the shoulder.
>>REQUEST A FOSAMAX LAWSUIT CONSULTATION<<
JAW PROBLEMS WITH FOSAMAX
Long term use of Fosamax has been linked to the painful and often disfiguring condition, osteonecrosis of the jaw (also referred to as ONJ, Dead Jaw or Bis-Phossy Jaw). Osteonecrosis of the jaw following use of Fosamax is often diagnosed after a dental procedure, such as a tooth extraction. More recent studies show that use of Fosamax can lead to osteonecrosis of the hip and osteonecrosis of the shoulder, as well as of the knee.
Merck, the manufacturer of Fosamax, knew about the risk of ostronecrosis of the jaw, but failed to take steps to properly warn patients, doctors and dentists. Saiontz & Kirk is currently investigating Fosamax lawsuit claims for individuals who have taken Fosamax and experienced jaw problems.
Recent studies have also suggested that Fosamax side effects may lead to decay and death of other bones besides the jaw, such as the hip, knee or shoulder.
FOSAMAX STATISTICS
Fosamax was approved in October 1995 by the US Food and Drug Administration (FDA). The drug was the first non-hormonal therapy treatment for postmenopausal osteoporosis in the United States.
- Fosamax and Fosamax Plus D are currently the most prescribed medicine for osteoporosis.
- In 2003, Fosamax was listed as the 19th most prescribed medication in the United States
- Nearly 20 million patients have been taken the drug.
- Fosamax averaged sales of more than $3 billion dollars a year for Merck as of 2005
>>INFORMATION: Fosamax Alternatives
LAWSUITS AGAINST FOSAMAX
If you or a family member have taken Fosamax and been diagnosed with osteonecrosis of the jaw, experienced symptoms of jaw death, or suffered from shoulder, hip or knee osteonecrosis, you should seek a free consultation regarding your legal rights. We can investigate your potential claim as a result of Merck’s failure to warn of the Fosamax side effects. Our Fosamax lawyers have the experience and resources to fight the pharmaceutical company and make sure you obtain the compensation you may be entitled to.
